{"id":"W2550828294","doi":"10.1182/blood.v110.11.389.389","title":"Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Neutropenia; Febrile neutropenia; Mantle cell lymphoma; Ibritumomab tiuxetan; Gastroenterology; Vincristine; Alemtuzumab; CHOP; Cyclophosphamide; Radioimmunotherapy; Surgery; Urology; Transplantation; Lymphoma; Chemotherapy; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004264412,0.002052835,0.002541576,0.0006726849,0.0005631067,0.0009445831,0.001636758,0.00185794,0.003545609],"category_scores_gemma":[0.00163105,0.001043116,0.001405214,0.0006776652,0.001660079,0.001018067,0.0004894336,0.00396209,0.00134164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001355271,"about_ca_system_score_gemma":0.002092632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001549397,"about_ca_topic_score_gemma":0.002187985,"domain_scores_codex":[0.9986172,0.0009025363,0.00005761127,0.0001604698,0.0001056648,0.0001564777],"domain_scores_gemma":[0.998538,0.0002806495,0.0002816751,0.0002112196,0.00007584885,0.0006126286],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7909505,0.1449087,0.006776305,0.0004121815,0.0009533375,0.0002312328,0.0002578585,0.001707015,0.02301704,0.000150452,0.001291695,0.02934364],"study_design_scores_gemma":[0.513341,0.4742197,0.008613874,0.00001836787,0.0002939186,0.0001243137,0.00003821751,0.0005833533,0.001773116,0.00008368371,0.0008932701,0.00001720441],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940823,0.0009415842,0.0004108367,0.0002017174,0.00009418451,0.00267471,0.0006077965,0.00005688507,0.0009299663],"genre_scores_gemma":[0.9877048,0.001362709,0.001767549,0.0007233699,0.0002583908,0.003912586,0.001897984,0.0000351294,0.002337554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004264412,"threshold_uncertainty_score":0.02255267,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01420086124735594,"score_gpt":0.3031764204823627,"score_spread":0.2889755592350068,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}